• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyrimidines Pyrrolo[2,3-d]pyrimidines

Professional Introduction to 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio) and Its CAS No. 29877-77-8

The compound 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio), identified by the CAS number 29877-77-8, represents a significant molecule in the realm of pharmaceutical chemistry and drug discovery. This heterocyclic compound belongs to the pyrrolopyrimidine class, a scaffold widely recognized for its structural versatility and biological activity. Pyrrolopyrimidines have garnered considerable attention due to their potential in modulating various biological pathways, making them valuable candidates for the development of therapeutic agents.

One of the most striking features of 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio) is its structural complexity, which allows for multiple points of functionalization. The presence of a chloro group at the 4-position and a methylthio group at the 2-position introduces unique reactivity that can be exploited in medicinal chemistry. These substituents not only enhance the compound's solubility and bioavailability but also contribute to its interaction with biological targets. The chloro group, in particular, is known to participate in various chemical reactions, including nucleophilic substitution, which can be leveraged in designing derivatives with enhanced pharmacological properties.

In recent years, there has been a surge in research focused on developing novel pyrrolopyrimidine derivatives as inhibitors of kinases and other enzymes involved in cancer progression. The compound 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio) has been investigated for its potential as a lead compound in this context. Studies have demonstrated that modifications at the 4- and 7-positions can significantly alter the binding affinity and selectivity of these molecules towards target enzymes. For instance, the chloro group at position 4 can be replaced with other halogens or alkyl groups to fine-tune the pharmacokinetic profile of the compound.

The methylthio group at position 2 adds another layer of complexity to the molecule's reactivity. This moiety can undergo oxidation or reduction reactions, allowing for further derivatization and exploration of its biological effects. Additionally, the presence of sulfur in the methylthio group may contribute to the compound's ability to interact with thiols present in biological systems, potentially leading to novel mechanisms of action. Such interactions are particularly relevant in developing drugs that target redox-sensitive pathways.

Recent advancements in computational chemistry have enabled researchers to predict the binding modes of these compounds with high accuracy. Molecular docking studies have shown that 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio) can effectively bind to active sites of kinases and other enzymes involved in cancer signaling pathways. These studies have provided valuable insights into how structural modifications can enhance binding affinity and selectivity. For example, replacing the chloro group with a fluorine atom has been found to improve metabolic stability while maintaining strong binding interactions.

The synthesis of 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio) involves multi-step organic reactions that require careful optimization to ensure high yields and purity. Common synthetic routes include condensation reactions between appropriately substituted pyrrole and pyrimidine derivatives followed by functional group transformations. The chlorination step is particularly critical and often involves electrophilic aromatic substitution reactions using reagents such as phosphorus oxychloride (POCl?). Similarly, the introduction of the methylthio group typically requires thiolation reactions using sodium thiolates or other sulfur-containing reagents.

From a pharmacological perspective, 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-7-methyl-2-(methylthio) has shown promise in preclinical studies as an inhibitor of tyrosine kinases involved in cancer cell proliferation. Early-phase clinical trials have reported encouraging results regarding its ability to disrupt signaling pathways that drive tumor growth. However, further research is needed to fully understand its safety profile and optimal dosing regimen. Combination therapies involving this compound with other anti-cancer agents may also be explored to enhance therapeutic efficacy.

The versatility of pyrrolopyrimidines as pharmacophores extends beyond oncology. These compounds have also been investigated for their potential in treating inflammatory diseases, infectious disorders, and neurological conditions. The structural features that make them effective kinase inhibitors also allow them to modulate other enzyme systems involved in these diseases. For instance, certain pyrrolopyrimidine derivatives have been found to inhibit Janus kinases (JAKs), which play a crucial role in inflammatory responses.

In conclusion,7H-Pyrrolo[2,3-d]pyrimidine, particularly its derivative 4-chloro-7-methyl-2-(methylthio) variant identified by CAS no., represents a promising scaffold for drug development with significant potential across multiple therapeutic areas. Its unique structural features provide opportunities for extensive molecular optimization through medicinal chemistry approaches such as structure-based drug design (SBDD) and fragment-based drug discovery (FBDD). As research continues to uncover new biological targets and mechanisms, this compound is poised to play an important role in shaping future therapeutic strategies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)